Uveal melanoma overview
|
Uveal melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Uveal melanoma overview On the Web |
|
American Roentgen Ray Society Images of Uveal melanoma overview |
|
Risk calculators and risk factors for Uveal melanoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Uveal melanoma is a cancer of the eye involving the iris, ciliary body, or choroid. Uveal melanoma arise from melanocytes in the uvea.[1] Uveal melanoma is a rare disease, but the most common primary intraocular malignancy.[2] Iris melanomas are less common than choroidal melanomas. Uveal melanoma may be classified into several subtypes based on their location, based on ophthalmoscopic examination and based on the cell type. According to the Callender classification, there are four subtypes of uveal melanoma based on the cell type. Genes involved in the pathogenesis of uveal melanoma include GNAQ, GNA11, and BAP1. Uveal melanoma is caused by a mutation in the DNA. The incidence of uveal melanoma in the United States is approximately .43 per 100,000 individuals. The majority of uveal melanoma cases are reported in Europe and United States. The incidence of uveal melanoma increases with age; the median age at diagnosis is 60 years. Males are more commonly affected with uveal melanoma than females. Uveal melanoma commonly affects individuals older than twenty years of age. Caucasians are more commonly affected with uveal melanoma than Africans.[3][4] Common risk factors in the development of uveal melanoma are cutaneous and iris nevi, host pigmentation factors, and ultraviolet light exposure, Caucasian race, and certain inherited skin disorders such as dysplastic nevus syndrome and ocular melanocytosis. If left untreated, 50% of patients with uveal melanoma may progress to develop metastasis. Common complications of uveal melanoma include glaucoma, vision loss, and metastasis. Prognosis is generally good for patients with iris melanoma, and the 10 year-survival for iris melanoma is approximately 95 percent and for ciliochoroidal tumors is 77 percent respectively.[5]Symptoms of uveal melanoma include eye pain, eye redness, loss of peripheral vision, poor or blurry vision in one eye, a dark spot on the iris, seeing flashing lights, floaters, and symptoms of glaucoma.[5] The optimal therapy for uveal melanoma depends on the size of the tumor. The various treatment modalities for uveal melanoma include enucleation, plaque brachytherapy, external beam proton therapy, transupillary thermotherapy, Gamma Knife stereotactic radiosurgery, and rection of the tumor.[4]
Historical Perspective
Classification
Uveal melanoma may be classified into several subtypes based on their location, based on ophthalmoscopic examination and based on the cell type. According to the Callender classification, there are four subtypes of uveal melanoma based on the cell type.
Pathophysiology
Genes involved in the pathogenesis of uveal melanoma include GNAQ, GNA11, and BAP1.
Causes
Uveal melanoma is caused by a mutation in the DNA.
Differential Diagnosis
Uveal melanoma must be differentiated from pigmenteed nevi, congenital hypertrophy of the retinal pigment epithelium, optic disc melanocytoma, hypertrophy of the retinal pigment epithelium, hyperplasia of retinal pigment epithelium, choroidal hemangioma, choroidal metastasis, choroidal osteoma, peripheral exudative hemmorhagic chorioretinopathy, choroidal hemmorhage, hemorrhagic detachment of retina and retinal pigment epithelium, posterior nodular scleritis, intraocular leiomyoma, adenoma of retinal pigment epithelium, retinoblastoma, uveal metastasis, choroidal detachment, choroidal hemangioma, choroidal cyst, uveal neurofibroma, and uveal schwannoma.[2][6]
Epidemiology and Demographics
The incidence of uveal melanoma in the United States is approximately .43 per 100,000 individuals. The majority of uveal melanoma cases are reported in Europe and United States. The incidence of uveal melanoma increases with age; the median age at diagnosis is 60 years. Males are more commonly affected with uveal melanoma than females. Uveal melanoma commonly affects individuals older than twenty years of age. Caucasians are more commonly affected with uveal melanoma than Africans.[3][4]
Risk Factors
Common risk factors in the development of uveal melanoma are cutaneous and iris nevi, host pigmentation factors, and ultraviolet light exposure, Caucasian race, and certain inherited skin disorders such as dysplastic nevus syndrome and ocular melanocytosis.
Screening
According to the United States Preventive Services Task Force, screening for uveal melanoma is not recommended.
Natural History, Complications and Prognosis
If left untreated, 50% of patients with uveal melanoma may progress to develop metastasis. Common complications of uveal melanoma include glaucoma, vision loss, and metastasis. Prognosis is generally good for patients with iris melanoma, and the 10 year-survival for iris melanoma is approximately 95 percent and for ciliochoroidal tumors is 77 percent respectively.[5]
Staging
According to the American Joint Committee on Cancer, there are four stages of uveal melanoma based on the tumor size, spread to nearby lymph nodes, and metastasis. Each stage is assigned a number 0 through 4 that indicate increasing severity and letters T, N, and M that designate the tumor size, spread to nearby lymph nodes, and metastasis respectively.[7]
History and Symptoms
Symptoms of uveal melanoma include eye pain, eye redness, loss of peripheral vision, poor or blurry vision in one eye, a dark spot on the iris, seeing flashing lights, floaters, and symptoms of glaucoma.[5]
Physical Examination
Common physical examination findings of uveal melanoma include presence of dark spot on the iris, anisicoria, loss of peripheral vision, decreased visual acuity and photopsia.
Laboratory Tests
Some patients with uveal melanoma may have elevated concentration of complete and differential blood counts and elevated liver enzyme levels, which is usually suggestive of metastasis of uveal melanoma to the liver.[4]
Chest X Ray
Chest x-rays may be performed to detect metastases of uveal melanoma to the lungs.
CT Scan
On head and neck CT scan, uveal melanoma is characterized by elevated, hyperdense sharply marginated lenticular or mushroom shaped lesions that enhance with administration of contrast.[2]
MRI scan
Head and neck MRI scan is diagnostic of uveal melanoma. On head and neck MRI, uveal melanoma is characterized by isointense to hypointense mass on T1-weighted MRI and hyperintense mass on T2-weighted MRI.[2]
Ultrasound
On ultrasound, uveal melanoma is characterized by internal vascularity, collar button shape, and solid low to medium echotexture.[2]
Other Imaging Studies
Other imaging studies of uveal melanoma include ultrasound biomicroscopy, optical coherence tomography, color fundus photography, fluorescein angiography, indocyanine green angiography, transillumination, and photography.[4]
Other Diagnostic Tests
Other diagnostic studies for uveal melanoma include PET scan.
Medical therapy
The optimal therapy for uveal melanoma depends on the size of the tumor. The various treatment modalities for uveal melanoma include enucleation, plaque brachytherapy, external beam proton therapy, transupillary thermotherapy, Gamma Knife stereotactic radiosurgery, and rection of the tumor.[4]
Surgical therapy
Surgery is the mainstay of treatment for uveal melanoma.[4]
Primary Prevention
Secondary Prevention
References
- ↑ Uveal melanoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Uveal_melanoma Accessed on October 27 2015
- ↑ 2.0 2.1 2.2 2.3 2.4 Retinoblastoma. Radiopedia(2015) http://radiopaedia.org/articles/primary-uveal-malignant-melanoma Accessed on October 27, 2015
- ↑ 3.0 3.1 van, J.G.M.; Koopmans, A.E.; Verdijk, R.M.; Naus, N.C.; de, A.; Kilic, E. (2013). "Diagnosis, Histopathologic and Genetic Classification of Uveal Melanoma". doi:10.5772/53631.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Uveal melanoma. National Cancer Institute(2015) http://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq Accessed on October 24 2015
- ↑ 5.0 5.1 5.2 5.3 Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013). "Ocular melanoma: an overview of the current status". Int J Clin Exp Pathol. 6 (7): 1230–44. PMC 3693189. PMID 23826405.
- ↑ Polednak AP (1975). "Letter: Asthma and cancer mortality". Lancet. 2 (7945): 1147–8. PMID 53631.
- ↑ Retinoblastoma. National Cancer institute(2015) http://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq#section/_100 Accessed on October 21, 2015